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RAPAMYCIN BUT NOT FK506 INHIBITS THE PROLIFERATION 
OF MONONUCLEAR PHAGOCYTES INDUCED BY 
COLONY-STIMULATING FACTORS! 
MARK H. COOPER,2 STEPHEN H. GREGORY,3,4 THOMAS E. STARZL,2 AND EDWARD J. WING,3 
Departments of Surgery and Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 
FK506, CsA, and rapamycin are potent inhibitors of 
T lymphocyte activation; relatively little is known of 
their effects on cells of the monocyte/macrophage lin-
eage_ Studies were undertaken to determine the ef-
fects of these drugs on the proliferative response of 
bone marrow-derived mononuclear phagocytes 
(BMMP) to CSFs. Rapamycin inhibited the prolifera-
tion of BMMP cultured in the presence of 10% L cell-
conditioned medium, used as a source of macrophage 
CSF. The inhibition by rapamycin was dose dependent 
and apparent at concentrations of 0.1 nM or greater. In 
a similar fashion, rapamycin inhibited the prolifera-
tion of BMMP stimulated by the recombinant forms of 
murine IL-3 and murine granulocyte-macrophage 
CSF, and human macrophage CSF. In contrast, neither 
FK506 nor CsA at concentrations as high as 1000 nM 
diminished the proliferation of BMMP cultured under 
identical conditions. FK506, but not CsA, blocked the 
inhibitory effects of rapamycin on the response of 
BMMP to CSFs. In summary, these data indicate that 
rapamycin inhibits the proliferation of BMMP in re-
sponse to CSFs. These results imply that patients re-
ceiving rapamycin, but not FK506 or CsA, may have an 
impaired ability to generate a functional mononuclear 
phagocyte population. 
FK506 and rapamycin are structurally related, macrolide 
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antibiotics derived from Streptomyces tsukubaensis (1--3) and 
Streptomyces hygroscopicus (4, 5), respectively. CsA, a cyclic 
peptide, is an unrelated fungal metabolite (6, 7). All 3 com-
pounds exhibit potent immunosuppressive activity in vivo 
(8-11) and in vitro (12-14). Although FK506 and CsA are 
structurally unrelated, they exhibit similar mechanisms of 
action. Both inhibit the early events in T cell activation that 
occur subsequent to antigen-TCR interaction and that culmi-
nate in the expression of early T cell activation genes (15). 
FK506 is 10-100 times more potent than CsA in suppressing 
the proliferation of mitogen- and alloantigen-activated T lym-
phocytes in vitro (12, 13). In addition, FK506 is more effec-
tive than CsA in suppressing graft rejection after organ 
transplantation in animal models (16). Both FK506 and CsA 
are used clinically to prevent graft rejection in humans (17, 
18). 
In contrast to either FK506 or CsA, rapamycin inhibits 
cytokine-driven T lymphocyte proliferation rather than the 
activation of cells induced by the antigen-TCR interaction 
(19). FK506 and rapamycin bind to the same intracellular 
protein, FK-binding protein (FKBP),* which is distinct from 
the intracellular binding site of CsA, cyclophilin (20--22). As 
a consequence, FK506 and rapamycin act as reciprocal an-
tagonists exerting mutually exclusive effects on T cell prolif-
* Abbreviations: BMMP, bone marrow-derived mononuclear 
phagocyte; FBS, fetal bovine serum; FKBP, FK-binding protein; GM-
CSF, granulocyte-macrophage colony-stimulating factor; LCM, L 
cell-conditioned medium; M-CSF, macrophage colony-stimulating 
factor; MTT, 3-( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; rh, recombinant human; rm, recombinant murine. 
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eration (13). Like FK506 and CsA, rapamycin effectively sup-
presses allograft rejection in animal models (23). 
While the effects of rapamycin, FK506, and CsA on T lym-
phocytes are well documented, less is known of the effects of 
these drugs on other immune cell types, including mono-
nuclear phagocytes. The proliferation and differentiation of 
bone marrow-derived mononuclear phagocytes (BMMP) from 
committed myeloid progenitors represent important features 
of the host's immune system (24). The growth factors respon-
sible for the generation of a functional mononuclear phago-
cyte population constitute a family of glycoproteins termed 
the colony-stimulating factors. These factors include macro-
phage CSF (M-CSF), which stimulates the maximum prolif-
eration of cells in this lineage, as well as granulocyte-macro-
phage CSF (GM-CSF) and IL-3. These CSFs may act alone or 
in combination to promote the proliferation and survival of 
BMMP in vivo and in vitro (24). 
The present study was undertaken to investigate the ef-
fects of rapamycin, FK506, and CsA on the ability of BMMP 
to proliferate in response to CSFs. Here we report that CSF-
driven BMMP proliferation is inhibited by pharmacological 
concentrations of rapamycin, but not of FK506 or CsA. These 
findings constitute one of the first reports to demonstrate 
that rapamycin differs from both FK506 and CsA in its effect 
on cells of the myeloid lineage. These data may have impor-
tant implications with regard to the clinical use of rapamy-
cin, FK506, and CsA in patients requiring immunosuppres-
sive therapy, and to the mechanisms that underlie growth 
factor signaling in mononuclear phagocytes. 
MATERIALS AND METHODS 
Animals. Eight- to 12-week-old female C57BU6J mice purchased 
from Jackson Laboratories, Bar Harbor, ME, were used in all experi-
ments. Animals were housed in accordance with the guidelines pro-
posed by the Institute of Laboratory Animals Resources, National 
Research Council. 
BMMP. BMMP were obtained as described previously (25, 26). 
Briefly, bone marrow was harvested from the femurs of mice killed by 
cervical dislocation. The cells were suspended in RPMI 1640 medium 
(Gibco BRL, Grand Island, NY) supplemented with 10% heat-inac-
tivated fetal bovine serum (FBS; Sterile Systems, Inc., Logan, UT), 
100 U/ml penicillin, 100 jIg/ml streptomycin, 20% heat-inactivated 
equine serum (Sterile Systems) and 20% serum-free L 929 cell-con-
ditioned medium (LCM), which served as a source of M-CSF. Bone 
marrow cells (2x105) in 20 ml of medium were seeded into 10-em 
bacteriological grade polystyrene petri dishes, and the cells were 
incubated at 37°C in a humidified atmosphere of 5% CO2 in air. On 
day 7 an additional 2 ml ofLCM were added to all cultures. The cells 
were harvested after 11 or 12 days incubation, at which time they 
constituted a pure, relatively immature population of BMMP (25, 
26). 
CSFs. Recombinant human (rh) M-CSF and recombinant murine 
(rm) GM-CSF were the generous gifts of Immunex Corp., Seattle, 
WA; rm1L-3 was purchased from Genzyme Corp., Boston, MA. In 
preliminary experiments, 10,000 U/ml rhM-CSF, 1,000 U/ml rmGM-
CSF, and 100 Ulml rmIL-3 stimulated the maximum proliferation of 
BMMP cultured under the conditions described. 
Immunosuppressants. Rapamycin and FK506 were gifts obtained 
from Wyeth-Ayerst Laboratories, Princeton, NJ, and from Fujisawa 
Pharmaceutical Co., Ltd., Osaka, Japan, respectively. CsA was ob-
tained from Sandoz Pharmaceuticals, Basel, Switzerland. Stock 
10-mM drug concentrations were prepared in absolute ethanol. Di-
lutions were made in RPMI 1640 medium supplemented with 10% 
FBS and antibiotics immediately before experimental use. 
Assay of the effect ofCSFs and drugs on the proliferation of BMMP. 
Microtiter plates were inoculated with BMMP suspended in RPMI 
medium supplemented with 10% FBS and antibiotics (5 x 103 cells! 
well) and the plates were incubated for 2 hr to allow the cells to 
attach. FK506, rapamycin, or CsA (ranging in concentration from 0.1 
nM to 1000 nM) was then added with or without LCM rhM-CSF 
rmGM-CSF, or rmlL-3 and cells were cultured for an' additionai 
period ranging from 4 hr to 7 days. 
Assessment of cell proliferation. The proliferation of BMMP was 
assessed by one of the following 3 methods. (a) Metabolism of 3-(4,5-
dimethylthiazol-2-yll-2,5-diphenyltetrazolium bromide (MTT): The 
ability of the BMMP to metabolize the tetrazolium salt MTI' was 
used as a measure of cell proliferation (27). The cells were incubated 
with 5 mg/ml MTT (Sigma Chemical Co., St. Louis, MO) during the 
last 4 hr of the culture period. To solubilize the formazan product of 
MTT metabolism, an equal volume of 10% SDS in 0.1 N HCI was 
added to each well and the plates were incubated for an additional 18 
hr at 37°C. The plates were read on a multiwell scanning spectro-
photometer (ELISA reader) using a 570-nm test filter and a 630-nm 
reference filter. 
(b) [3H]Thymidine incorporation: The cells were pulsed with 1 
].lCi/well [methyPHlthymidine (ICN, Costa Mesa, CAl during the 
last 18 hr of the culture period. The cells were collected using an 
automated cell harvester and [3Hlthymidine incorporated into DNA 
was determined by liquid scintillation counting. 
(c) Quantitation of cell number: The number of cells per well was 
assessed by lysing the cells with a 3% solution ofhexadecyltrimeth-
ylammonium bromide (Fisher Scientific Co., Fair Lawn, NJ) and 1 
mM EDTA in 0.85% saline, and counting the nuclei microscopically 
using a hemocytometer (28, 29). 
Can A-induced splenocyte proliferation. Freshly isolated mouse 
splenocytes were suspended in RPMI 1640 medium supplemented 
with 10% FBS, 1 mM sodium pyruvate, 1 mM L-glutamine, 1% 
essential and nonessential amino acids, 5X 10-5 M 2-ME, 100 U/ml 
penicillin, and 100 Jlg/ml streptomycin. The cells were seeded into 
microtiter plates (lxl05 cells/well) and incubated 3 days in the pres-
ence or absence of 1 ].lg/ml Con A and FK506, rapamycin, or CsA 
ranging in concentration from 0.1 to 1000 nM. [3H1Thymidine incor-
poration into DNA during the last 18 hr of the culture period was 
used as a measure of cell proliferation. 
Statistical analysis. Means were compared using a nonpaired Stu-
dent's t test; P<0.05 was statistically significant. 
RESULTS 
Rapamycin inhibits the proliferative response of BMMP to 
10% LeM. Studies were performed to examine the effects of 
rapamycin, CsA, and FK506 on the kinetics of BMMP prolif-
eration in response to 10% LCM, used as a source ofM-CSF. 
Proliferation was assessed in terms of the ability of cells to 
metabolize the tetrazolium salt MTT. As shown in Figure 1, 
the inhibitory effect of 10 nM rapamycin on cell proliferation 
was evident on days 3, 5, and 7 of a 7 -day incubation period. 
In contrast, neither FK506 nor CsA exerted an adverse effect 
on the proliferation ofBMMP during this time. It is pertinent 
to note that none of the 3 immunosuppressants tested af-
fected the degeneration or death of cells characteristic of 
BMMP cultured in the absence of an exogenous source of 
CSFs. Over the course of a 3-day incubation period, BMMP 
cultured in the absence of added CSFs exhibited a 5- to 10-
fold loss in capacity to metabolize MMT regardless of 
whether FK506, CsA, or rapamycin was present at concen-
trations ranging from 0.001 to 1000 nM (data not shown). 
Rapamycin inhibits the proliferation of BMMP in a dose-
dependent fashion. Rapamycin, CsA, and FK506 were tested 
over a broad range of concentrations for their effects on the 
proliferative response of BMMP to 10% LCM. These effects 
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FIGURE 1. Growth kinetics of BMMP cultured in the presence of 
CsA, FK506, or rapamycin. BMMP (5X 103/6-mm well) were cultured 
in the presence of 10% LCM with or without 10 nM CsA, FK506, or 
rapamycin. Cell proliferation was assessed by the addition of M'IT 
during the last 4 hr ofthe culture period. Values are the means::+: SD 
OD570-63o derived from 4 identical wells in 1 experiment representa-
tive of 5 similar experiments. Cell growth in cultures that contained 
rapamycin was significantly less on days 3, 5, and 7 (P<O.OOl). 
were analyzed on the fifth day of incubation when the pro-
liferation of cells peaked in control, untreated cultures. Rapa-
mycin inhibited BMMP proliferation in response to LCM in a 
dose-dependent fashion (Fig. 2). Significant inhibitory effects 
were noted with 0.1 nM rapamycin; rapamycin at 10 nM or 
greater inhibited cell proliferation maximally. Neither FK506 
nor CsA at concentrations ranging from 0.1 to 1000 nM af-
fected the proliferation of cells cultured in the presence of 
10% LCM. 
Cell proliferation assessed in terms of MTT metabolism 
correlates with tritiated thymidine incorporation and cell 
number. To ensure that the results obtained by analysis of 
MTT metabolism were a true reflection of BMMP prolifera-
tion, cell number and [3HJthymidine incorporation into DNA 
were used in parallel experiments to assess proliferation. The 
addition of 10 nM rapamycin to BMMP cultured in the pres-
ence of 10% LCM resulted in a 50% decrease in MTT metabo-
lism relative to untreated control cultures (Table 1). Simi-
larly, cell cultures that contained rapamycin exhibited an 
approximate 75% decrease in both [3H]thymidine incorpora-
tion and cell number. Neither FK506 nor CsAhad an effect on 
BMMP proliferation as determined by each of the 3 assays. 
Rapamycin inhibits the proliferative response of BMMP to 
the recombinant forms of human M-CSF, murine GM-CSF, 
and lL-3. The effects of rapamycin, CsA, and FK506 on the 
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FIGURE 2. Rapamycin inhibits BMMP proliferation in a dose-de-
pendent fashion. BMMP (5x103/6-mm well) were incubated in the 
presence of 10% LCM and increasing concentrations of CsA, rapa-
mycin, or FK506. On the fifth day of culture, MTT metabolism was 
used to assess cell proliferation. Data are the means:+: SD OD571)..630 
readings obtained from 4 identical wells in 1 experiment. Three 
similar experiments gave comparable results. Cells treated with 
rapamycin were significantly less than untreated control cells at all 
concentrations tested (P<O.OOl). 
TABLE 1. Rapamycin inhibits the proliferation of BMMP: 
correlation between MTT metabolism, [3H]thymidine 
incorporation, and cell numbera 
MTT Metabolism [3HlTbymidine Cell 
Drug 2 incorporation number/well (OD57O-<130XIO) (cpm) (X 10-3) 
Control 
Rapamycin 
FK506 
CsA 
13.9:+:0.35 
7.2::+:0.14b 
15.0::+:0.25 
14.8::+:0.59 
13,125::+: 1,650 
3,210:+:890 b 
10,798:+:4,873 
14,827::+:1,922 
13.2::+:3.3 
3.0:+:0.8b 
12.1::+:2.6 
11.6::+:2.7 
a BMMP (5X 103 cells/6-mm well) were cultured in the presence of 
10% LCM with or without rapamycin, FK506, or CsA at 10 nM 
concentrations. All assessments of proliferation were performed on 
day 5. Data are the means ::+: SD of 4 identical wells obtained in a 
single experiment representative of 3 similar experiments. 
b Significantly less than the comparable control value, P<O.OOl. 
proliferative response of BMMP to recombinant CSFs corre-
lated with their effects on the response of cells to LCM. Rapa-
mycin at a concentration equal to or greater than 10 nM 
inhibited the proliferation ofBMMP cultured in the presence 
of rhM-CSF (Fig. 3A); rapamycin (2: 0.1 nM) inhibited the 
proliferation of cells induced by rmIL-3 (Fig. 3B). In addition, 
1000 nM rapamycin inhibited the proliferation of cells cul-
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tured in the presence of rmGM-CSF (Fig. 3C). In contrast, 
neither FK506 nor CsA at concentrations ranging from 0.1 to 
1000 nM adversely affected the proliferative response of cells 
to rhM-CSF, rmGM-CSF, or rmIL-3. In fact, the addition of 
1000 nM FK506 appeared to increase the growth of BMMP 
cultured in the presence of rhM-CSF and rmIL-3. CsA at 
1000 nM had a similar effect on the growth of cells cultured 
in the presence of rmIL-3. 
Rapamycin, FK506, and CsA inhibit the proliferative re-
sponse of splenocytes to Can A. Experiments were performed 
to compare the effects of rapamycin, FK506, and CsA on 
mitogen-stimulated splenocyte proliferation to their effects 
on BMMP proliferation. Normal mouse splenocytes were cul-
tured in the presence of 1 JIg/ml Con A and increasing con-
centrations of drug. Splenocytes cultured with either FK506 
or rapamycin at concentrations equal to or greater than 0.1 
nM and 0.001 nM, respectively, exhibited a marked reduction 
in cell proliferation relative to cells cultured in the absence of 
drugs (Fig. 4). Significant inhibition by CsA was observed at 
concentrations of 10 nM and greater. Thus, FK506 and CsA 
at pharmacological concentrations that had no effect on the 
proliferation of BMMP strongly suppressed the blastogenic 
response of splenocytes to Con A. In contrast, rapamycin at 
comparable concentrations inhibited the proliferation of both 
BMMP and splenocytes. 
FK506, but not CsA, antagonizes the inhibitory effects of 
rapamycin on BMMP proliferation. FK506, but not CsA, an-
tagonizes the inhibitory effect of rapamycin on the prolifera-
tive response of T lymphocytes to selected stimuli, i.e., IL-2 
and PMA (13). Experiments were undertaken, therefore, to 
determine whether FK506 also antagonized the effect of 
rapamycin on the proliferative response of BMMP to CSFs. 
As shown in Figure 5, rapamycin inhibited the proliferation 
of cells cultured in the presence of 10% LCM; FK506 and CsA 
had no effect. The inhibitory effect of rapamycin on BMMP 
proliferation was prevented by the addition of an equimolar 
concentration of FK506. CsA failed to prevent the inhibitory 
effect of rapamycin on BMMP proliferation. 
DISCUSSION 
Previous studies have given little attention to the effects of 
immunosuppressants on the response of myeloid cells to 
CSFs. In the present study, pharmacological concentrations 
of rapamycin inhibited the proliferation of murine BMMP 
cultured in the presence of LCM, a source of M-CSF. Inhibi-
tion was evident regardless of the method used to assess cell 
growth, i.e., MTT metabolism, [3H]thymidine incorporation, 
or quantitation of cell number. The effect of rapamycin was 
dose dependent and apparent at concentrations comparable 
FIGURE 3. Rapamycin inhibits the proliferative response of BMMP 
to rhM-CSF, rmGM-CSF, and rmIL-3. BMMP (5X 103 cells/well) were 
incubated in the presence oHA) 10,000 Ulml rhM-CSF, (B) 100 Ulml 
rmIL-3, or (C) 1000 Ulml rmGM-CSF and increasing concentrations 
of FK506, rapamycin, or CsA. MTT metabolism was determined on 
day 5 of culture. Data are the means ± SD OD570--63o derived from 
quadruplicate wells in single experiments representative of at least 
3 similar experiments. Values obtained from untreated and drug-
treated cultures are significantly different: (A) P<O.OOl for rapamy-
cin at 10 nM and 1000 nM; (B) P<O.OOl for rapamycin at 0.1 nM, 10 
nM, and 1000 nM, and P<O.OOl for FK506 and CsA at 10 nM and 
1000 nM; (e) P<0.02 for rapamycin at 1000 nM. 
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FIGURE 4. Rapamycin, FK506, and CsA inhibit the proliferation of 
Con A-stimulated splenocytes. Splenocytes (1 x 105/6-mm well) were 
cultured for 3 days in the presence or absence of 1 J.lg/ml Con A and 
increasing concentrations of CsA, FK506, or rapamycin. The cells 
were pulsed with 1 ].lCi/well [3HJthymidine during the last 18 hr of 
the culture period. Data are the means ± SD cpm incorporated by 
cells in 4 identical wells in an experiment representative of 3 similar 
experiments. Values obtained for cells treated with concentrations of: 
rapamycin 2: 10-3 nM; FK506 2: 0.1 nM; and CsA 2: 10 nM are 
statistically less than the values obtained for the untreated controls 
(P<0.005). 
to those that inhibited the blastogenic response of mouse 
splenocytes to Con A. Similarly, rapamycin blocked the pro-
liferation of BMMP cultured in the presence of rhM-CSF, 
rmGM-CSF, and rmIL-3. In contrast, FK506 and CsA failed 
to inhibit the proliferation of BMMP at drug concentrations 
that inhibited Con A-induced blastogenesis of splenocytes. 
None of the 3 immunosuppressants tested prohibited the 
death of BMMP cultured in the absence of CSFs. This latter 
finding suggests that the inhibitory effect of rapamycin on 
the proliferation of BMMP was exerted specifically on the 
response of cells to CSFs. 
These findings correlate with published reports demon-
strating that different mechanisms underlie the effects of 
FK506 and CsA compared with rapamycin on the activation 
or proliferation of T lymphocytes (12, 13). FK506 and CsA 
inhibit the early, calcium-dependent events in T cell activa-
tion that occur subsequent to antigen-TCR interactions (30). 
These early events are distinguished by the accumulation of 
intracellular calcium leading to the elevated expression of 
early phase activation genes which encode growth-promoting 
cytokines such as IL-2 and IL-4 (15). While both FK506 and 
CsAinhibit the production ofIL-2 and IL-4 by T lymphocytes, 
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FIGURE 5. FK506 reverses the inhibitory effect of rapamycin on 
BMMP proliferation. BMMP (5X103/well) were cultured in the pres-
ence of 10% LCM with or without CsA, FK506, or rapamycin (10 nM 
final concentrations) added singularly or in the combinations shown. 
Cell proliferation was assessed by MTT metabolism on the fifth day 
of culture. Data are the means ± SD laRT~PM obtained from qua-
druplicate wells in a single experiment. Comparable results were 
obtained in 2 similar experiments. The values obtained for cells 
incubated with rapamycin alone or in combination with CsA are 
significantly less than the values obtained for untreated control cells 
(P<O.OOl). 
neither impairs the calcium-independent proliferative re-
sponse of cells to such cytokines (13). Rapamycin, on the 
other hand, inhibits the response of T cells to IL-2 and IL-4 
without blocking cytokine production. Thus, it has been sug-
gested that complexes formed between rapamycin and its 
cytosolic receptor preferentially block the signal transduction 
pathways used by growth factors (19). 
FK506, CsA, and rapamycin exert effects on other immune 
cells that are similar to their effects on T lymphocytes. For 
example, FK506 and CsA inhibit the antigen receptor-medi-
ated, calcium-dependent activation ofB lymphocytes, but not 
the calcium-independent proliferative response ofB lympho-
cytes to mitogens such as LPS or 8-mercaptoguanosine (31, 
32). Similarly, FK506 and CsA inhibit the IgE receptor-me-
diated exocytosis of pharmacological mediators by human 
mast cells (33-35). Rapamycin, on the other hand, blocks the 
mitogenic response of B lymphocytes to LPS and 8-mercap-
toguanosine, and has no effect on receptor-mediated exocyto-
sis exhibited by mast cells. 
The contrasting effects of FK506 and rapamycin on cell 
activation are somewhat surprising in view of their struc-
tural similarity and their apparent affinity for the same in-
tracellular binding protein, FKBP (30). The affinity ofFK506 
and rapamycin for the same cytosolic receptor was first sug-
gested by studies demonstrating their capacity to act as re-
ciprocal antagonists during the activation of murine T lym-
438 TRANSPLANTATION Vol. 57, No.3 
p~ocytes (13). It was later found that rapamycin readily 
displaced FK506 from FKBP in a competitive binding assay 
E~SFK More recent studies suggested that FK506 and rapamy-
cm also compete for a common intracellular receptor in B 
lymphocytes (31) and mast cells (34). Similarly, in the study 
reported here, FK506 reversed the inhibitory effect of rapa-
myc~n on the proliferative response of BMMP to CSFs, sug-
gestmg that FK506 and rapamycin may compete for a com-
mon intracellular receptor in BMMP. CsA did not prevent 
rapamycin-mediated suppression of BMMP proliferation. 
This is consistent with its interaction with an entirely differ-
ent intracellular binding protein, cyclophilin (21, 22). 
Further studies have helped to clarify the mechanisms 
that underlie the immunosuppressive effects ofFK506, rap a-
mycin, and CsA, and to resolve the different effects of FK506 
and rapamycin on T cell activation. It is now believed that the 
biological activities of these immunosuppressants are medi-
ated by complexes formed hetween the drugs and their intra-
cellular binding proteins. For CsA and FK506, these com-
plexes (CsA-cyclophilin and FK506-FKBP, respectively) bind 
and inactivate calcineurin, a protein phosphatase that plays 
a critical role in the early, calcium-dependent events that 
culminate in T cell activation (37, 38). In this regard, it is 
relevant to note that the mitogenic response of BMMP to the 
CSFs occurs in the apparent absence of calcium involvement 
(39). Thus, the failure of FK506 and CsA to suppress the 
proliferative response of BMMP to the CSFs implies that 
calcineurin is not a critical component of the activation path-
way. While rapamycin binds to the same cytosolic receptor as 
FK506, available data suggest that the rapamycin-FKBP 
complex interacts with a molecule(s) other than calcineurin 
affecting the activation ofT lymphocytes by calcium-indepen-
dent mechanisms, e.g., those that mediate the response of 
cells to cytokines such as IL-2 and IL-4 (38). Our findings 
indicate that the proliferative response of BMMP to CSFs, 
similar to the response of T lymphocytes to IL-2 or IL-4, is 
mediated by a Ca + +/calcineurin-independent pathway. 
The findings reported here have important implications in 
view of the potential use of rapamycin, FK506, and CsA in a 
general clinical setting. Based upon experimental data dem-
onstrating the efficacy of FK506 in preventing organ allograft 
rejection (11), autoimmune diseases (8), and graft-versus-
host disease after allogenic BMT (40), clinical trials involving 
FK506 are proceeding in the United States and Europe. 
Clinical use of rapamycin is presently restricted to dose-re-
sponse trials conducted only in certain centers. Since the 
proliferative response of BMMP to CSFs is an integral fea-
ture of hematopoiesis and host defenses (24), it is more likely 
that patients receiving rapamycin would be compromised in 
their abilities to generate a functional mononuclear phago-
cyte population and to respond to infection. On the other 
hand, the capacity of rapamycin to suppress BMMP prolif-
eration could be used in the treatment of certain diseases, 
e.g., granulomatous diseases such as histiocytosis or leprosy, 
in which BMMP play an integral role in the pathogenesis. 
Thus, careful consideration given to the potent inhibitory 
effects of rapamycin on BMMP proliferation should allow 
rapamycin to be used in an efficacious manner. 
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